
CLAIMS

1. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein:

(a) an initial dose of the pharmaceutical composition comprising 250 to 400 mg of a compound of Formula (II) is to be administered within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

(b) a plurality of subsequent doses of the pharmaceutical composition, wherein each of said plurality of subsequent doses comprises 100 to 300 mg of a compound of Formula (II), are to be administered at intervals of 24 hours until there is an improvement in the infection or between from 1 day to 10 days, Formula (II) having the following structure,



(II),


or a pharmaceutically acceptable salt thereof.

2. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein:

(a) an initial dose of the pharmaceutical composition comprising 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, or 225 mg of a compound of Formula (II) is to be administered within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

(b) a plurality of subsequent doses of the pharmaceutical composition, wherein

each of said plurality of subsequent doses comprises 100 to 300 mg of a compound of Formula (II), are to be administered at intervals of 24 hours until there is an improvement in the infection or between from 1 day to 10 days, Formula (II) having the following structure,



(II),

or a pharmaceutically acceptable salt thereof.

3. The use of Claim 1, wherein an initial dose comprising 300 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 250 mg to 300 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

4. The use of Claim 2, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

5. The use of Claim 1, wherein an initial dose comprising 400 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg to 200 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

6. The use of Claim 1, wherein an initial dose comprising 300 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject

at intervals of 24 hours for 1-5 days.

7. The use of Claim 2, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 200 mg to 250 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

8. The use of Claim 2, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 250 mg to 300 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

9. The use of Claim 2, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

10. The use of Claim 2, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 200 mg to 250 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

11. The use of Claim 2, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 250 mg to 300 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

12. The use of Claim 2, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg to 200 mg of the compound are to be administered to the

human subject at intervals of 24 hours for 1-5 days.

13. The use of Claim 2, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg to 200 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

14. The use of Claim 1, wherein an initial dose comprising 300 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 200 mg to 250 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

15. The use of Claim 1, wherein an initial dose comprising 300 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg to 200 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

16. The use of Claim 1, wherein an initial dose comprising 400 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

17. The use of Claim 1, wherein an initial dose comprising 400 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 200 mg to 250 mg of the compound are to be administered to the human subject at intervals of 24 hours for 1-5 days.

18. The use of Claim 1, wherein an initial dose comprising 400 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 250 mg to 300 mg of the compound are to be administered to the human subject at

intervals of 24 hours for 1-5 days.

19. The use of any one of Claims 1-18, wherein the dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

20. The use of any one of Claims 1-19, wherein the dengue viral infection is secondary dengue infection.

21. The use of any one of Claims 1-20, wherein the human subject to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.